You are here

The Open Secret about the HER2 Assay with Jim Vaught

Guest:

Jim Vaught, Editor-in-Chief, Biopreservation and Biobanking Journal Bio and Contact Info

Listen (6:50) The importance of better biosamples only recognized in the past 10 to 15 years

Listen (2:30) Is there still some convincing to do?

Listen (3:39) A new biospecimen science

Listen (6:55) The HER2 story

Listen (8:46) What can be done ?

Much of biomedical research is carried out on biospecimen samples. Yet the quality of samples used varies a great deal. This directly affects research outcomes for the worse.

Unfortunately, it’s become quite passé to say that a majority of biological research cannot be reproduced. This issue has been addressed recently by the head of the NIH, Francis Collins, and many others, and yet rarely do we hear that much of the problem is actually in the degradation of the samples studied.

Advertisement:

Today we begin a new series Back to Basics: Improving Biospecimens, where we’ll look at some of the issues around biosamples. What is involved in sample collection? How do these issues affect drug development? What are we learning from the new science of sampling, and what can we do to raise standards?

To start us off, we’re joined by Jim Vaught, Editor in Chief of the Biopreservation and Biobanking Journal. Jim gives a great introduction to the topic of biosampling and offers a striking example, that of the HER2 assay, that demonstrates why we must bring more attention to improving biospecimens.

Podcast brought to you by: Quintiles - bringing people and knowledge together for a healthier world.